The Far-Reaching Consequences Of The
Pharmaceutical Business With The AIDS Epidemic

  1. It goes without saying that the pharmaceutical investment interests are trying to do everything to keep the multibillion Rand investment market with patented ARV drugs alive. Worse, as an investment industry they do everything to expand this ARV drug market – i.e. to expand the AIDS epidemic under the pretext of fighting it.
  2. The marketing strategy behind this pharmaceutical approach to AIDS as well as the devastating global consequences are well documented, but little known: The World Health Organization (WHO) defined AIDS in an official conference in Bangui , Central Africa , as the occurrence of five typical “AIDS-defining symptoms.” They are: fever, diarrhoea, persistent cough, weight loss and TB symptoms.
  3. To expand their global markets with AIDS drugs, the pharmaceutical industry has consistently tried to reduce the problem of AIDS to a simple equation, the infection with the human immunodeficiency virus (HIV). It is currently vigorously debated whether the pharmaceutical equation HIV=AIDS is a scientific fact or a marketing strategy for the promotion of ARV drugs.
  4. The answer to this question is surprisingly simple and comes from WHO data as recent as 2001 (Annexure ‘WHO Data 2001’). The statistical evaluation of these unique global data show that:
    1. From all people infected with HIV statistically less than 20 % develop the immune deficiency condition AIDS – even after 13 years.
    2. This means that after more than a decade over 80% of all HIV-infected individuals remain AIDS free.
    3. If HIV were the highly pathogenic micro-organism that it is being promoted to be by pharmaceutical medicine, AIDS-symptoms would occur in about 100% of the cases – and within a relatively short time.
    4. While HIV may be present in AIDS patients it cannot be the only cause of AIDS.
  5. On the other hand, the statistical evaluation of large scale clinical studies using ARV drugs in HIV-positive patients show a distinctly different picture (Annexures ‘Palella’, ‘Hogg’):
    1. The death rate from AIDS among HIV-positive patients taking ARVs is statistically at least 7% each year.
    2. This means that almost 100% of those patients taking toxic ARVs have developed AIDS and have died after 13 years.
  6. Several important conclusions can be drawn from these facts which are summarized in the attached graph (Annexure ‘WHO HIV-graph’):
    1. While the majority of HIV-positive patients not taking ARVs have an 80% chance to survive 13 years AIDS free, the statistical chances to survive this period for patients taking ARVs are close to zero.
    2. The promotion of ARV drugs to all HIV positive patients is not based on scientific facts nor does it help the patients. It is solely built on marketing strategies of pharmaceutical companies selling ARVs and looking to expand their drug markets.
    3. The only way to cause AIDS symptoms in about 100% of HIV infected people is to promote toxic ARVs to them – immediately after they have been diagnosed as HIV positive.
  7. Considering these facts the need for effective, safe and affordable alternatives is paramount. Even if they are not cures for HIV either, the minimum they can accomplish is to strengthen the immune system of patients affected by immune deficiencies/AIDS – and not aggravate these conditions.